Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study

Merck and ​Eisai's ‌experimental combination treatments ​for ​a type ⁠of ​kidney ​cancer failed to meet ​the ​main goals ‌of ⁠a late-stage study, the ​companies ​said ⁠on ​Tuesday.